issue, dedicated to diabetes, cover-to-cover, reviewed the cited references, and carefully studied The Lancet editorial. To my amazement, there was not one mention of metabolic/ bariatric surgery, the only proven method of resolving the clinical and laboratory manifestations of type 2 diabetes in about 80% of patients [1][2][3][4]. Though this technology is not suitable or available to all type 2 diabetics, it is an alternative for millions of people and, most importantly, metabolic/bariatric surgery is a clinical laboratory for diabetes research.The Lancet reflects clinical acumen in this critical area of diabetes management and, thereby, serves the role of a global university for educating the medical profession. This role makes it imperative that The Lancet not ignore and omit mention of the evidencebased literature findings contributed by metabolic/ bariatric surgery.